DOCSLIB.ORG

Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome Jaime C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome Jaime C Clin Drug Investig 2011; 31 (10): 675-689 REVIEW ARTICLE 1173-2563/11/0010-0675/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome Jaime C. Branco,1,2 Ana Maria Tome´,3,4 Manuel R. Cruz5 and Augusto Filipe3 1 CEDOC, Faculdade de Cieˆncias Me´dicas da Universidade Nova de Lisboa, Lisbon, Portugal 2 Servic¸o de Reumatologia do CHLO, EPE/Hospital Egas Moniz, Lisbon, Portugal 3 Medical Department, Grupo Tecnimede, Sintra, Portugal 4 Faculty of Life Sciences, University of Hertfordshire, Hatfield, UK 5 Centro Hospitalar Psiquia´trico de Lisboa, Lisbon, Portugal Contents Abstract. 675 1. Introduction . 676 2. Literature Search Methodology . 676 3. Burden of Disease and Current Pharmacological Treatment Options . 677 3.1 Depression . 677 3.2 Fibromyalgia Syndrome . 677 4. Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome . 678 4.1 Pharmacological Characteristics . 679 4.1.1 Pharmacokinetics in Humans . 679 4.1.2 Pharmacodynamics in Humans . 679 4.2 Clinical Experience in Depression . 680 4.2.1 Placebo-Controlled Studies . 680 4.2.2 Active Comparator-Controlled Studies . 680 4.2.3 Non-Comparative Studies. 684 4.3 Clinical Experience in Fibromyalgia Syndrome . 684 4.4 Safety and Tolerability. 685 4.4.1 Drug Interactions . 686 5. Conclusions. 686 Abstract Depression and fibromyalgia syndrome are debilitating chronic condi- tions that impose a significant burden on individuals, families and society. Both depression and fibromyalgia have many overlapping symptoms, and antidepressants of several classes are among recommended treatment options for patients with fibromyalgia syndrome. Pirlindole is a selective and re- versible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in some European and non-European countries for the treatment of depression. The antidepressant efficacy and safety of pirlindole have been demonstrated in a number of placebo- and active comparator-controlled studies and are supported by many years of clinical experience in the treat- ment of depression. The drug’s efficacy and safety have also been demon- strated, more recently, in the treatment of fibromyalgia syndrome. Pirlindole 676 Branco et al. has a favourable tolerability profile, with no deleterious effect on cardio- vascular dynamics. The effect of pirlindole on sensorimotor performance relevant to driving a motor vehicle is similar to that of placebo, as pirlindole appears to have an activating rather than a sedating antidepressant profile. Because of its specific and reversible inhibition of MAO-A and relatively short elimination half-life, no tyramine or ‘cheese’ effect is likely after short- or long-term administration. The available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome. 1. Introduction pirlindole is approved in Portugal and other coun- tries for the treatment of depression. This review Depression is a mood disorder characterized summarizes the evidence for the efficacy and by persistent episodes of loss of interest or plea- tolerability of pirlindole in the management of sure in ordinary activities, and experiences and depression and fibromyalgia syndrome. feelings of helplessness, hopelessness and worth- lessness, accompanied by additional symptoms 2. Literature Search Methodology such as changes in sleep, appetite or weight, and decreased energy, feelings of inadequacy, and Articles included in the current review were difficulty concentrating or making decisions.[1] all randomized, placebo- or active comparator- Fibromyalgia syndrome is a debilitating chronic controlled trials or systematic reviews published medical condition that causes diffuse and/or spe- in English between January 1970 and January cific pain throughout the soft tissues that support 2011 and identified via a search of MEDLINE and move the bones and joints.[2] Associated so- and EMBASE using the keywords (‘pirlindole’ matic and psychological symptoms include fa- OR ‘pirlindol’ OR ‘pyrazidol’) AND (‘depression’ tigue, sleep disturbances, cognitive impairment, OR ‘depressive disorder’ OR ‘antidepressant’ OR nervousness, depression and headaches.[2,3] Both ‘fibromyalgia’ OR ‘fibromyalgia syndrome’). This depression and fibromyalgia syndrome are dis- literature search was supplemented by AdisBase, tressing and common disorders that impose a a proprietary database of Wolters Kluwer Health/ considerable burden on individuals, their families Adis. Additional references were identified from and society.[4-10] the reference lists of published articles and sup- Fibromyalgia syndrome and depression have plied on request from the reference files of Grupo many overlapping symptoms and often occur to- Tecnimede, Sintra, Portugal. The inclusion of gether.[2,3,11] In fibromyalgia syndrome, a psychic placebo-controlled trials in the current review co-morbidity with variables such as anxiety and may provide further insight into the efficacy of depression adversely affects the perception of dis- pirlindole not necessarily provided by analysis of ease severity, functional capacity, and the experi- trials comparing pirlindole with other active ence and tolerance of pain.[12] Furthermore, there agents. In clinical trials of patients with psychia- is emerging evidence that similar candidate genes tric disorders, placebo response rates are often high, may be implicated in both fibromyalgia syndrome and vary considerably;[15,16] the average placebo and depression, with polymorphisms of genes response rate in trials of patients with depression involved in the serotonergic, dopaminergic and has been estimated at 35–45%.[15] Consequently, catecholaminergic systems contributing to the placebo-controlled trials are important to dem- aetiology of fibromyalgia syndrome.[13,14] onstrate the efficacy of a drug,[16] as many trials The selective and reversible inhibitor of mono- of psychiatric disorders fail to confirm superi- amine oxidase (MAO) subtype A (MAO-A) [RIMA] ority of a drug over placebo.[15] ª 2011 Adis Data Information BV. All rights reserved. Clin Drug Investig 2011; 31 (10) Pirlindole in Depression and Fibromyalgia 677 3. Burden of Disease and Current comparable between and within classes.[21,22] How- Pharmacological Treatment Options ever, as the likely adverse events profiles of anti- depressant medications differ, the selection of an 3.1 Depression antidepressant should take tolerability, safety and cost into consideration, as well as patient pref- Depression has been identified by the WHO as erence and the previous treatment response to a [17] a leading cause of global burden of disease. particular drug.[1,21,22] While newer classes of anti- Worldwide, between 4% and 10% of the popula- depressants, such as selective serotonin reuptake tion is likely to experience major depression during inhibitors (SSRIs), noradrenergic reuptake in- [1] their lifetime, and population-based systematic hibitors and serotonin-norepinephrine reuptake reviews of the global burden of mental disorders inhibitors are considered first-line choices, the estimate a median 1-year rate of major depressive use of non-selective MAO inhibitors (MAOIs) [18] disorder of 5.3%. A recent survey-based study has declined because of the necessity for dietary of general medical practices in six European restrictions, adverse events related to their non- countries (UK, Spain, Portugal, Slovenia, Estonia selective and irreversible binding profile, and the and the Netherlands) found a prevalence rate of potential for drug-drug interactions.[1,21-23] The major depressive disorder of 12.2% in consecutive limitations of non-selective MAOIs, which irre- [19] practice attendees. Depression was more than versibly bind to both MAO-A and MAO-B iso- 60% more prevalent in women than in men, with enzymes, led to the development of RIMAs with the highest overall prevalence for women being improved tolerability and safety profiles; these observed in Spain, Portugal and the UK (18.4%, include pirlindole and moclobemide. As MAO-A [19] 17.8% and 13.2%, respectively). The impact of preferentially deaminates norepinephrine and major depression on functioning and quality of serotonin, inhibition of MAO-A is recognized as life (QOL) is illustrated in figure 1. a key factor for antidepressant effect.[28] Choosing an effective treatment strategy for patients with depression is guided by the duration 3.2 Fibromyalgia Syndrome and severity of the condition.[1,21-23] A wide range of effective pharmacological treatment options is The recent European League Against Rheu- available for depression (summarized in table I). matism (EULAR) multidisciplinary taskforce Although there are some suggestions of the su- described fibromyalgia syndrome as a common periority of one mechanism of antidepressant rheumatological condition characterized by chron- action over another, for the majority of patients ic widespread pain and reduced pain threshold, the effectiveness of antidepressants is generally with hyperalgesia and allodynia.[2] The prevalence Depressed mood Emotional pain Loss of interest Loss of pleasure Feelings of guilt Pessimistic feelings Physical pain Depression Low self-worth Poor concentration Sleep disorders Appetite loss/gain Fatigue Atypical physical Clinically significant complaints distress or impairment of functioning Fig. 1. Impact of major depression on functioning and quality of life including symptoms identified in the Diagnostic and Statistical
Load more

Recommended publications
  • 'Gating' Residues Ile199 and Tyr326 in Human Monoamine Oxidase B
    The ‘gating’ residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition Erika M. Milczek1,*, Claudia Binda2, Stefano Rovida2, Andrea Mattevi2 and Dale E. Edmondson1 1 Departments of Chemistry and Biochemistry, Emory University, Atlanta, Georgia, USA 2 Department of Genetics and Microbiology, University of Pavia, Italy Keywords The major structural difference between human monoamine oxidases A dipartite to monopartite cavity conversion; (MAO A) and B (MAO B) is that MAO A has a monopartite substrate inhibitor specificity; monoamine oxidase B; cavity of 550 A˚3 volume and MAO B contains a dipartite cavity struc- mutations of gating residues; structure of ture with volumes of 290 A˚3 (entrance cavity) and 400 A˚3 (substrate methylene blue complex cavity). Ile199 and Tyr326 side chains separate these two cavities in MAO Correspondence B. To probe the function of these gating residues, Ile199Ala and Ile199Ala- D. E. Edmondson, Department of Tyr326Ala mutant forms of MAO B were investigated. Structural data on Biochemistry, Emory University, 1510 the Ile199Ala MAO B mutant show no alterations in active site geometries Clifton Road, Atlanta, GA 30322, USA compared with wild-type enzyme while the Ile199Ala-Tyr326Ala MAO B Fax: +1 404 727 2738 mutant exhibits alterations in residues 100–103 which are part of the loop Tel: +1 404 727 5972 gating the entrance to the active site. Both mutant enzymes exhibit catalytic E-mail: [email protected] properties with increased amine KM but unaltered kcat values. The altered *Present address KM values on mutation are attributed to the influence of the cavity struc- Department of Chemistry, Princeton ture in the binding and subsequent deprotonation of the amine substrate.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0011643 A1 Dilisa Et Al
    US 2015 0011643A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0011643 A1 DiLisa et al. (43) Pub. Date: Jan. 8, 2015 (54) TREATMENT OF HEART FAILURE AND (60) Provisional application No. 61/038,230, filed on Mar. ASSOCATED CONDITIONS BY 20, 2008, provisional application No. 61/155,704, ADMINISTRATION OF MONOAMINE filed on Feb. 26, 2009. OXIDASE INHIBITORS (71) Applicants:Nazareno Paolocci, Baltimore, MD Publication Classification (US); Univeristy of Padua, Padova (IT) (51) Int. Cl. (72) Inventors: Fabio DiLisa, Padova (IT): Ning Feng, A63L/38 (2006.01) Baltimore, MD (US); Nina Kaludercic, (52) U.S. Cl. Baltimore, MD (US); Nazareno CPC ..... ... A61 K31/138 (2013.01) Paolocci, Baltimore, MD (US) USPC .......................................................... S14/651 (21) Appl. No.: 14/332,234 (22) Filed: Jul. 15, 2014 (57) ABSTRACT Related U.S. Application Data Administration of monoamine oxidase inhibitors is useful in (63) Continuation of application No. 12/407,739, filed on the prevention and treatment of heart failure and incipient Mar. 19, 2009, now abandoned. heart failure. Patent Application Publication Jan. 8, 2015 Sheet 1 of 2 US 201S/0011643 A1 Figure 1 Sial 8. Sws-L) Cleaved Š Caspase-3 ) Figure . Prevention of caspase-3 productief) fron cardiomyocytes Lapoi) reatment with clorgyi Be. Patent Application Publication Jan. 8, 2015 Sheet 2 of 2 US 201S/0011643 A1 Figure 2 8:38:8 ::::::::8: US 2015/0011643 A1 Jan. 8, 2015 TREATMENT OF HEART FAILURE AND in the art is a variety of MAO inhibitors and their pharmaceu ASSOCATED CONDITIONS BY tically acceptable compositions for administration, in accor ADMINISTRATION OF MONOAMINE dance with the present invention, to mammals including, but OXIDASE INHIBITORS not limited to, humans.
    [Show full text]
  • Attendee Guidelines
    (Temple of Eternal Sound) Attendee Guidelines 1. Introduction 2. Practical Guidelines -Preparation -Contraindications -Food -Clothing -Cleansing -During the Session -Suggested Best Practices -Temple Practices & Ritual Norms -Single Sacrament Sanctuary 3. Code of Ethics 4. Dietary Guidelines 5. Medical Information 6. Attendee Waiver Céu do Som Welcome, Thank you for your interest in our Forest Family Circles, Realisation Retreats and Wisdom Works at the Temple of Céu do Som & Abuelatree Sanctuary. You are endeavouring to participate in what, for us, is one of the most profound and meaningful doorways into the mysteries of the Sacred & Profound. The following pages are practical suggestions outlining our expectations, guidelines and safety measures to ensure harmony for you, for our work and for our community. We seek to uphold a high standard in regards to the safe space of transformation and realisation that may create a positive impact through healing and integration of our participants. The guidelines in this booklet all serve a direct purpose. We ask that each one be approached with due respect. It is not necessary to subscribe to our points of view in order to receive the sacrament. We do not discriminate and find that ultimately it is up to the individual to discover what is true for them. Así Céu do Som PRACTICAL GUIDELINES Preparation for the spiritual study Contraindications (refer to Medical Information section for more details) 1. If you are uncertain about any contraindications or factors please ask. 2. If you have any personal concerns a meeting can be arranged prior in order to discuss. 3. If you are taking any prescription medication, namely antidepressants, antipsychotics or SSRI's please speak to us (Refer to Medical Information section).
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Mikocka-Walus Et Al-2017
    This is a repository copy of Adjuvant therapy with antidepressants for the management of inflammatory bowel disease (Protocol). White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/118724/ Version: Published Version Article: Mikocka-Walus, Antonina Anna orcid.org/0000-0003-4864-3956, Fielder, Andrea, Prady, Stephanie Louise orcid.org/0000-0002-8933-8045 et al. (3 more authors) (2017) Adjuvant therapy with antidepressants for the management of inflammatory bowel disease (Protocol). Cochrane Database of Systematic Reviews. ISSN 1469-493X https://doi.org/10.1002/14651858.CD012680 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Adjuvant therapy with antidepressants for the management of inflammatory bowel disease (Protocol) Mikocka-Walus A, Fielder A, Prady SL, Esterman AJ, Knowles S, Andrews JM Mikocka-Walus A, Fielder A, Prady SL, Esterman AJ, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period
    Supplementary Online Content Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naïve patients in the postoperative period. JAMA Intern Med. Published online July 11, 2016. doi:10.1001/jamainternmed.2016.3298. eTable 1. List of CPT Codes eFigure. Sample Construction Flow Chart eTable 2. List of Drug Classes eTable 3. List of Medical Comorbidities and ICD-9 Codes eTable 4. Sample Summary Characteristics, by procedure eTable 5. Risk Factors for Chronic Opioid Use Following Surgery Among Opioid Naïve Patients This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 1. List of CPT codes CPT Codes Total Knee Arthroplasty1 27447 Total Hip Arthroplasty1 27130 Laparoscopic Cholecystectomy2 47562, 47563, 47564 Open Cholecystectomy3 47600, 47605, 47610 Laparoscopic Appendectomy4 44970, 44979 Open Appendectomy5 44950, 44960 Cesarean Section6 59510, 59514, 59515 FESS7 31237, 31240, 31254, 31255, 31256, 31267, 31276, 31287, 31288 Cataract Surgery8 66982, 66983, 66984 TURP9 52601, 52612, 52614 Simple Mastectomy10‐12 19301, 19302, 19303, 19180 © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eFigure. Sample Construction Flow Chart © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 2.
    [Show full text]
  • Racionalno Načrtovanje Potencialnih Antidepresivov Iz Skupine Reverzibilnih Inhibitorjev Monoamin-Oksidaze A
    Diplomsko delo Racionalno načrtovanje potencialnih antidepresivov iz skupine reverzibilnih inhibitorjev monoamin-oksidaze A Junij, 2017 Marko Breznik Marko Breznik Racionalno načrtovanje potencialnih antidepresivov iz skupine reverzibilnih inhibitorjev monoamin-oksidaze A Diplomsko delo Maribor, 2017 Racionalno načrtovanje potencialnih antidepresivov iz skupine reverzibilnih inhibitorjev monoamin-oksidaze A Diplomsko delo univerzitetnega študijskega programa I. stopnje Študent: Marko Breznik Študijski program: univerzitetni študijski program I. stopnje Kemija Predvideni strokovni naslov: diplomirani kemik (UN) Mentor: izr. prof. dr. Urban Bren Komentor: dr. Janez Konc Maribor, 2017 Racionalno načrtovanje potencialnih antidepresivov iz skupine RIMA Kazalo .......................................................................................................................................... IV Kazalo................................................................................................................................... I Izjava .................................................................................................................................. II Zahvala .............................................................................................................................. III Povzetek ............................................................................................................................ IV Abstract .............................................................................................................................
    [Show full text]
  • Antidepressant Treatment for Postnatal Depression
    This is a repository copy of Antidepressant treatment for postnatal depression. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/163986/ Version: Published Version Article: Brown, Jennifer Valeska Elli orcid.org/0000-0003-0943-5177, Wilson, Claire A., Ayre, Karyn et al. (5 more authors) (2020) Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. CD013560. ISSN 1469-493X https://doi.org/10.1002/14651858.CD013560 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Library Cochrane Database of Systematic Reviews Antidepressant treatment for postnatal depression (Protocol) Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013560. DOI: 10.1002/14651858.CD013560. www.cochranelibrary.com Antidepressant treatment for postnatal depression (Protocol) Copyright © 2020 The Cochrane Collaboration.
    [Show full text]
  • Patil AJ and Suryawanshi MR. Review on Novel Monoamine Oxidase Inhibitors: a Clinician’S Guide
    Open Access Journal of Pharmaceutical Research ISSN: 2574-7797 MEDWIN PUBLISHERS Committed to Create Value for Researchers Review on Novel Monoamine Oxidase Inhibitors: A Clinician’s Guide Patil AJ and Suryawanshi MR* Mini Review Department of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Poona College of Volume 5 Issue 2 Pharmacy, India Received Date: March 04, 2021 Published Date: June 02, 2021 Mugdha R Suryawanshi, Department of Pharmaceutical Chemistry, *Corresponding author: DOI: 10.23880/oajpr-16000240 Poona College of Pharmacy, Bharati Vidyapeeth Deemed to be University, Pune 411038, India, Tel: 9011032733; Email: [email protected] Abstract The purpose of this review is to provide information on the mechanisms of action, pharmacokinetics, therapeutic effectiveness, safety, and tolerability of four novel antidepressants: pirlindole, safinamide, selegiline, and toloxatone. In spite of the initial pharmacological interest, monoamine oxidase (MAO) inhibitors are used in clinics for their antidepressant effects and in the treatment of Parkinson’s syndrome due to proven neuroprotective effects. Patients with a lack of efficacy or tolerability for some monoamine oxidase inhibitors may benefit from the option of a new one monoamine oxidase inhibitors with various mechanism of actions. In the selection of newer monoamine oxidase inhibitors, these drugs may be an alternative. The simple deficiency of serotonin in the brain does not cause depression, but rather a complex interplay of different neurotransmitters, planincluding of treatment, some regions the ambiguity of the brain of include the underlying serotonin, neurobiological norepinephrine, process dopamine should and be histamine. considered. The novel monoamine oxidase inhibitors described above exert their therapeutic advantages by acting on multiple neurotransmitters.
    [Show full text]
  • Adjuvant Therapy with Antidepressants for the Management of Inflammatory Bowel Disease
    This is a repository copy of Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/144907/ Version: Published Version Article: Mikocka-Walus, Antonina Anna orcid.org/0000-0003-4864-3956, Prady, Stephanie Louise orcid.org/0000-0002-8933-8045, Pollok, J et al. (4 more authors) (2019) Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database of Systematic Reviews. CD012680. ISSN 1469-493X https://doi.org/10.1002/14651858.CD012680.pub2 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Adjuvant therapy with antidepressants for the management of inflammatory bowel disease (Review) Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.
    [Show full text]
  • INCB 01158-202 Protocol Amendment 2 (Version 2 Dated 01 JUN 2018) and Agree to Conduct the Study As Outlined
    Incyte Corporation Page 1 of 146 Protocol INCB 01158-202 Am 2 Version 2 01 JUN 2018 Clinical Study Protocol INCB 01158-202 An Open-Label, Multicenter, Nonrandomized, Dose-Escalation, and Tumor-Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat (INCB024360), With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors Product: INCB001158 IND Number: 136,524 EudraCT Number: 2017-002716-13 Phase of Study: 1/2 Sponsor: Incyte Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 Original Protocol (Version 0): 02 OCT 2017 Date of Amendment (Version) 1: 27 OCT 2017 Date of Amendment (Version) 2: 01 JUN 2018 This study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and conducted in adherence to the study Protocol, Good Clinical Practices as defined in Title 21 of the US Code of Federal Regulations Parts 11, 50, 54, 56, and 312, as well as ICH GCP consolidated guidelines (E6) and applicable regulatory requirements. The information in this document is confidential. No part of this information may be duplicated, referenced, or transmitted in any form or by any means (electronic, mechanical, photocopy, recording, or otherwise) without the prior written consent of Incyte Corporation. CONFIDENTIAL Incyte Corporation Page 2 of 146 Protocol INCB 01158-202 Am 2 Version 2 01 JUN 2018 INVESTIGATOR'S AGREEMENT I have read the INCB 01158-202 Protocol Amendment 2 (Version 2 dated 01 JUN 2018) and agree to conduct the study as outlined. I agree to maintain the confidentiality of all information received or developed in connection with this Protocol.
    [Show full text]